First-Line Ipilimumab-Nivolumab Matches Trial Progression-Free Survival in Chinese Kidney Cancer Study
A retrospective study of 60 Chinese patients with metastatic renal cell carcinoma receiving first-line ipilimumab plus nivolumab showed progression-free survival ...




















